Latest articles about Measles       Routine vaccines: Measles       Routine vaccines: Rubella

Gavi’s impact

The global number of reported cases more than doubled from 2017

Over 118 million children reached with measles or measles-rubella vaccine through routine immunisation

More than 524 million children immunised through measles and measles-rubella vaccination campaigns


While 2018 saw some progress in efforts to protect more children against measles, including successful immunisation campaigns in some of the largest Gavi-supported countries, the overall picture was not positive. The global number of reported cases more than doubled from 2017. Stagnating coverage rates led to multiple measles outbreaks worldwide, including in Gavi-supported countries such as India and Madagascar. Just 14 of the initial 73 Gavi-supported countries have been certified as having eliminated measles as a public health problem.


By the end of 2018, our support for a second dose of measles vaccine through the routine immunisation system had helped immunise more than 76 million children. This support provides a second opportunity to reach children who missed the first dose. It also produces immunity in the small number of people who failed to develop it after the first dose. Since the programme start, Gavi has also reached over 42 million children with a first and/or second dose of measles-rubella vaccine.


In order to have a long-term impact on both measles and rubella control, we have invested more than US$ 600 million in large-scale measles-rubella catch-up campaigns since 2012. This catalytic support requires countries to introduce MR vaccines into their routine system after a campaign. Gavi also supports measles and measles-rubella follow-up campaigns to address immunity gaps in the population and help build population immunity.

So far, over 275 million children have been immunised through Gavi-supported measles-rubella catch-up and follow-up campaigns, and over 249 through Gavi-supposed measles follow-up campaigns. Nationwide measles-rubella catch-up campaigns target all children aged 9 months to 14 years, while follow-up campaigns target children aged 9–59 months every 2–5 years.

The issue 

Measles remains one of the top vaccine-preventable killers of children.

Rubella infection in early pregnancy can result in foetal death or birth defects.

Measles remains one of the top vaccine-preventable killers of children.

Rubella infection in early pregnancy can result in foetal death or birth defects.


Measles is a highly contagious virus and remains one of the top vaccine-preventable killers of children. Symptoms include high fever and a severe skin rash.  

Thanks to the widespread introduction of measles vaccine, global measles deaths have fallen dramatically. Before 2001, more than 750,000 children died every year from measles.  

But even with this impressive decline, progress has stalled, and the number of cases even increased in several countries. Outbreaks continue across Africa and Europe, with children under the age of five most affected. More than 95% of measles deaths occur in low-income countries with weak health systems.  

Rubella is no longer the threat it once was in many countries, thanks to widespread vaccination. But for millions of mothers and their children in low-income countries, it poses an ongoing danger. When a woman is infected with the rubella virus early in pregnancy, she has a 90% risk of passing the virus on to her foetus. This can cause miscarriage, stillbirth or severe birth defects known as congenital rubella syndrome (CRS).  

Every year, more than 100,000 babies are born with CRS - the majority in Africa and South-East Asia. Although the rubella vaccine has been available since the 1970s, it is still underused in these regions. 

Gavi’s response

Gavi’s support for measles and rubella vaccines is a game-changer in the control of two deadly and debilitating diseases.

Gavi’s support for measles and rubella vaccines is a game-changer in the control of two deadly and debilitating diseases.


2017 marked the first year of Gavi-supported measles vaccine introductions and campaigns under our new measles and rubella strategy. The bulk of our support for measles vaccine is allocated towards the combined measles-rubella (MR) vaccine, which also provides protection against congenital rubella syndrome.  

The revised approach involves increases in both vaccine support and introduction grants, as well as enhanced technical assistance from Alliance partners. It aims to help countries deliver high-quality plans, implementation and evaluation of routine programmes and campaigns. For instance, countries are required to conduct independent surveys to track campaign coverage.

During 2017, we increased our collaboration with the Measles & Rubella Initiative, which led to clear results in 2018. Focusing on the six countries with the highest number of underimmunised children led to successful immunisation campaigns in Nigeria and Pakistan – using polio eradication workers and systems, and enhanced collaboration between Alliance partners. This resulted in unprecedented levels of coverage: 89% in Nigeria and 93% in Pakistan, close to the 95% level required to confer herd immunity and with large numbers of previously unimmunised children reached.

Given the importance of increasing the number of people protected from measles, the Board also agreed to allow greater flexibility in the use of operational cost support funds to conduct more targeted activities. Burundi, Lesotho, Senegal and Zambia are among the countries expected to make use of this new flexibility.

The results from these campaigns and the options surrounding these flexibilities are good news, but they are no substitute for sustainable routine immunisation.


  • Measles and measles-rubella routine immunisation

Gavi supports a first and second dose of the MR vaccine, as well as second dose measles vaccines. Countries contribute to the cost of these Gavi-supported vaccines by co-financing some of the required doses.

Supporting a second dose of the vaccine provides a second opportunity to reach children who missed the first dose. It also produces immunity in the small number of persons who failed to develop it after the first dose

  • Measles follow-up campaigns  

Nationwide follow-up campaigns immunise children aged 9–59 months every 2–5 years with measles vaccine. These campaigns are aimed at addressing gaps in measles immunity in the population that is not reached through routine immunisation.

  • Measles-rubella catch-up and follow-up campaigns

Gavi provides support for measles-rubella vaccine catch-up campaigns before the MR vaccine is introduced into the routine system. The campaigns target children aged 9 months to 14 years. By catalysing the vaccine’s introduction into the routine immunisation system, they help to ensure long-term impact on both measles and rubella control efforts.

Measles-rubella follow-up campaigns are also supported by Gavi once the vaccine has been introduced into routine immunisation. Similar to measles follow-up campaigns, these campaigns are aimed at addressing gaps in measles immunity in the population.

  • Measles outbreak response (through the Measles & Rubella Initiative)

Gavi provided US$ 55 million to the Measles & Rubella Initiative (M&RI, formerly the Measles Initiative) for the 2013–2017 period. The funding is used for outbreak response in Gavi-supported countries.

M&RI is a global partnership committed to ensuring no child dies from measles or is born with congenital rubella syndrome. It is led by the American Red Cross, the United Nations Foundation, the U.S. Centers for Disease Control and Prevention, UNICEF and WHO. The M&RI aims to achieve the measles and rubella elimination goals outlined in the Global Vaccine Action Plan.

From other sites

Latest articles about Measles and measles-rubella

After measles, a life in the dark

Not so long ago, measles was the leading cause of childhood blindness in poor countries. Vaccination and vitamin A supplementation helped – but now measles cases are again on the rise. In Ethiopia, VaccinesWork spoke to sightless survivors.

Spreading the word: Raising awareness of second-dose measles vaccine in Côte d’Ivoire

When a new vaccine is introduced, it can take concerted efforts to build up coverage levels. In Bouaké North-East district in Cote d’Ivoire, tireless engagement with communities and mobilisation of community health workers helped to boost…

Measles is one of the deadliest and most contagious infectious diseases – and one of the most easily preventable

A pediatrician and preventive medicine physician explains how measles vaccines became victims of their own success and the risk that rising outbreaks pose to everyone.

Vaccination and supportive care stave off deaths in Ugandan measles outbreak

With a sizeable cohort of unimmunised children built up over years, the measles epidemic is expected to grow among communities lining the lakeshore in Hoima district.  

Lao PDR receives over 650,000 doses of measles and rubella vaccine with support from Gavi

The Government of the Lao People’s Democratic Republic (PDR) has received over 650,000 doses of measles and rubella (MR) vaccine to help protect against and prevent the spread of the two illnesses, as part of Gavi’s support to the country’s…

How misinformation is fuelling the current measles crisis

With measles cases spiking amid falling vaccination rates in many parts of the world, it’s important to fight vaccine hesitancy alongside ensuring better access to vaccines.

New data shows “staggering” increase in measles deaths worldwide

Some 136,000 people died of measles in 2022, a 43% increase on 2021, amid a protracted slump in immunisation rates.

Increase in Measles Deaths Demands Urgent Action to Save Lives

Since 2001, the Measles and Rubella Partnership (M&RP) has worked with countries to vaccinate millions of children, helping to prevent an estimated 57 million deaths.

The Viral Most Wanted: Matonaviruses and Togaviruses

Multiple lines of enquiry against Chikungunya virus and its viral relatives are being pursued by scientists around the world, with the hope for a new protective vaccine coming very soon. 

Why do measles survivors get sicker?

Measles is one of the major causes of death among children, even though there is a safe and effective vaccine against it. 

From measles to malaria: infectious diseases that can damage your vision

The list of infectious diseases that can affect our eyesight is long, and several can lead to outright blindness. Luckily, many are preventable with vaccines.

South Sudan’s nationwide anti-measles campaign pays off

Awerial County’s vaccine blind spots included cattle camps and a remote lake island, but April’s ambitious mobile outreach efforts have calmed the early year’s spike in cases.

How to apply for vaccine support

Gavi Support Guidelines

Eligible countries can access detailed guidelines to manage the support they receive from Gavi.

Last updated: 18 Apr 2024

Subscribe to our newsletter